EVE Health Group Limited (AU:EVE) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EVE Health Group Limited reported a revenue downturn of 8% and a 53% decrease in net loss for members in FY 2024, with no dividends paid during the period. The company has seen success with its Meluka brand in the Australian market, achieving 17% growth, while strategically divesting non-core assets, including the sale of tea tree properties and a U.S. distribution business. These changes reflect EVE’s focus on its core health and wellness products and the Australian market, amid efforts to improve its financial footing.
For further insights into AU:EVE stock, check out TipRanks’ Stock Analysis page.